Liver Transplant Workup: Introduction
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Laparoscopy As a Diagnostic Tool in Ascites of Unknown Origin: a Retrospective Study Conducted at Kasturba Hospital, Manipal
Research Article Open Access J Surg Volume 8 Issue 3 - March 2018 Copyright © All rights are reserved by Chetan R Kulkarni DOI: 10.19080/OAJS.2018.08.555740 Laparoscopy as a Diagnostic Tool in Ascites of Unknown Origin: A Retrospective Study Conducted at Kasturba Hospital, Manipal Chetan R Kulkarni1*, Badareesh Laxminarayan2 and Annappa Kudva3 1Assistant Professor, Department of Surgery, Kasturba Hospital, Manipal 2Associate Professor, Department of Surgery, Kasturba Hospital, Manipal 3Professor, Department of Surgery, Kasturba Hospital, Manipal Received: February 16, 2018; Published: March 01, 2018 *Corresponding author: Chetan R Kulkarni, Assistant Professor, Department of Surgery, Kasturba Hospital, Manipal, India. Tel: 9535974395;Email: Abstract Background: Laparoscopy as a minimally invasive technique has long played an important role in the evaluation of ascites. Methods: A retrospective analysis was carried out on the record of 80patients who underwent laparoscopy after appropriate investigations had failed to reveal the cause of ascites. Results: Tuberculous peritonitis was reported in 46(57%), malignancies in 18(25%), cirrhosis in 4(5%) and peritonitis of unknown etiology in 8(10%)Conclusion: of patients. Two (2.5%) patients had complications, an Ileal perforation and in other Incisional hernia. Keywords: Ascites;Laparoscopy Diagnostic was Laparoscopy able to diagnose the pathology in 72 (90%) patients with ascites of unknown origin. Introduction Laparoscopy, as a minimally invasive technique has developed rapidly in recent years. Endoscopic examination of conventional laboratory examinations (including ascitic fluid cell count, albumin level, total protein level, Gram stain, culture who termed it as “Celioscopy” [1,2]. The term ‘ascites’ refers to and cytology ) as well as after imaging investigations (including peritoneal cavity was first attempted in 1901 by George Kelling Materialultrasound andand CT Methods scan). -
Recurrent Pneumothorax Following Abdominal Paracentesis
Postgrad Med J (1990) 66, 319 - 320 © The Fellowship of Postgraduate Medicine, 1990 Postgrad Med J: first published as 10.1136/pgmj.66.774.319 on 1 April 1990. Downloaded from Recurrent pneumothorax following abdominal paracentesis P.J. Stafford Department ofMedicine, Newham General Hospital, Glen Road, Plaistow, London E13, UK. Summary: A 62 year old man presented with abdominal ascites, without pleural effusion, due to peritoneal mesothelioma. He had chronic obstructive airways disease and a past history of right upper lobectomy for tuberculosis. On two occasions abdominal paracentesis was followed within 72 hours by pneumothorax. This previously unreported complication of abdominal paracentesis may be due to increased diaphragmatic excursion following the procedure and should be considered in patients with preexisting lung disease. Introduction Abdominal paracentesis is a widely used palliative right iliac fossa. Approximately 4 litres of turbid therapy for malignant ascites and is generally fluid was drained over 72 hours. The protein accepted as a procedure with few adverse effects: concentration was 46 g/l and microbiology and pneumothorax is not a recognized complication. I cytology were not diagnostic. Laparoscopy re- report a patient with recurrent pneumothorax vealed matted loops of bowel with widespread apparently precipitated by abdominal paracen- peritoneal seedlings. Histological examination of copyright. tesis. these lesions showed malignant mesothelioma of the epithelioid type. The patient suffered a left pneumothorax within Case report 48 hours ofparacentesis (before laparoscopy). This was treated with intercostal underwater drainage A 62 year old civil servant presented with a 6-week but recurred on two attempts to remove the drain, history ofworsening abdominal distension. -
Acute Liver Failure J G O’Grady
148 Postgrad Med J: first published as 10.1136/pgmj.2004.026005 on 4 March 2005. Downloaded from REVIEW Acute liver failure J G O’Grady ............................................................................................................................... Postgrad Med J 2005;81:148–154. doi: 10.1136/pgmj.2004.026005 Acute liver failure is a complex multisystemic illness that account for most cases, but a significant number of patients have no definable cause and are evolves quickly after a catastrophic insult to the liver classified as seronegative or of being of indeter- leading to the development of encephalopathy. The minate aetiology. Paracetamol is the commonest underlying aetiology and the pace of progression strongly cause in the UK and USA.2 Idiosyncratic reac- tions comprise another important group. influence the clinical course. The commonest causes are paracetamol, idiosyncratic drug reactions, hepatitis B, and Viral seronegative hepatitis. The optimal care is multidisciplinary ALF is an uncommon complication of viral and up to half of the cases receive liver transplants, with hepatitis, occurring in 0.2%–4% of cases depend- ing on the underlying aetiology.3 The risk is survival rates around 75%–90%. Artificial liver support lowest with hepatitis A, but it increases with the devices remain unproven in efficacy in acute liver failure. age at time of exposure. Hepatitis B can be associated with ALF through a number of ........................................................................... scenarios (table 2). The commonest are de novo infection and spontaneous surges in viral repli- cation, while the incidence of the delta virus cute liver failure (ALF) is a complex infection seems to be decreasing rapidly. multisystemic illness that evolves after a Vaccination should reduce the incidence of Acatastrophic insult to the liver manifesting hepatitis A and B, while antiviral drugs should in the development of a coagulopathy and ameliorate replication of hepatitis B. -
Intestinal and Multiple Organ Transplantation 1679
1678 TRANSPLANT ATION euglycemia and survive longer than 200 islets in allogeneic and xenogeneic diabetic hosts. Transplant Proc 1993; 25:953-954. 67. Gotoh M, Maki T, Satomi S, et al: Immunological characteristics of purified islet grafts. Transplantation 1986; 42j387. 68. Klima G, Konigsrainer A, Schmid T, et al: Is the pancreas reo jected independently of the kidney after combined pancreatic renal transplantation? Transplant Proc 1988; 20:665. 69. Prowse 5J, Bellgrau D, Lafferty KJ: Islet allografts are destroyed by disease recurrence in the spontaneously diabetic BB rat. Di abetes 1986; 35:110. 70. Markmann JF, Posselt AM, Bassiri H, et al: Major-histocompat ibility-complex restricted and nonrestricted autoil1'\mune effec tor mechanisms in BB rats. Transplantation 1991; 52:662-667. 71. Navarro X, Kennedy WR, Loewenson RB, et al: Influence of pancreas transplantation on cardiorespiratory reflexes, nerve conduction, and mortality in diabetes mellitus. Diabetes 1990; 39:802. 72. Weber q, Silva FG, Hardy MA, et al: Effect of islet transplan tation on renal function and morphology of short- and long term diabetic rats. Transplant Proc 1979; 11:549. 73. Gotzche 0, Gunderson HJ, Osterby R: Irreversibility of glomer ular basement membrane accumulation despite reversibility of renal hypertrophy with islet transplantation in early diabetes. Diabetes 1981; 30:481. 74. Fung H, Alessini M, Abu-Elmagd K, et al: Adverse effects asso ciated with the use ofFK 506. Transplant Proc 1991; 23:3105. 75. Tzakis AG: Personal communication, 1991. I CHAPTER 185 Figure 185-1. Cluster allograft (shaded portion), including the liver, pancreas, and duodenal segment of small intestine. (From Starzl TE, Todo S. -
Septicaemia After Colonoscopy in Patients With
450 Gut, 1991,32,450-451 Septicaemia after colonoscopy in patients with cirrhosis Gut: first published as 10.1136/gut.32.4.450 on 1 April 1991. Downloaded from j R Thornton, M S Losowsky Abstract PATIENT 2 Two patients with ulcerative colitis and In 1987, a 34 year old man underwent routine chronic active hepatitis with cirrhosis, who colonoscopy because ofhis ulcerative colitis of 12 developed Gram negative septicaemia after years' duration. Twenty three years earlier a colonoscopy are described. These and two liver biopsy had shown that he had chronic similar reported cases indicate that giving active hepatitis and cirrhosis. Hepatitis B prophylactic antibiotics to patients with cir- markers were negative. In 1983 he developed rhosis undergoing colonoscopy should be con- ascites and had remained on spironolactone since sidered, particularly when the cirrhosis is then. advanced. At the time ofhis colonoscopy he claimed that he felt reasonably well and was continuing to work. However, he had a moderate amount of Prophylactic antibiotics have been advised for ascites. His medication was: prednisolone 5 mg patients undergoing colonoscopy who have daily, spironolactone 200 mg daily, and sul- valvular heart disease, cardiac prostheses, severe phasalazine 1 g twice daily. Preoperative blood immunodepression, or hepatic cirrhosis with tests were: bilirubin 53 ,umol/1, alanine amino- ascites.' The last of these recommendations is transferase 38 IU/, alkaline phosphatase 206 IU/ based on a single case report in which it was not 1, albumin 28 g/l, prothrombin time 16 seconds certain that colonoscopy was responsible for the (control 14 seconds). infection, as hepatic angiography was performed After bowel preparation with three litres of the day before peritonitis developed.' We were Golytely, colonoscopy to the caecum was per- unaware of this case but our recent experience formed. -
Differential Metabolism of Alprazolam by Liver and Brain Cytochrome (P4503A) to Pharmacologically Active Metabolite
The Pharmacogenomics Journal (2002) 2, 243–258 2002 Nature Publishing Group All rights reserved 1470-269X/02 $25.00 www.nature.com/tpj ORIGINAL ARTICLE Differential metabolism of alprazolam by liver and brain cytochrome (P4503A) to pharmacologically active metabolite HV Pai1,2* ABSTRACT SC Upadhya1,2* Cytochrome P450 (P450) is a superfamily of enzymes which mediates metab- 1 olism of xenobiotics including drugs. Alprazolam, an anti-anxiety agent, is SJ Chinta * metabolized in rat and human liver by P4503A1 and P4503A4 respectively, SN Hegde1 to 4-hydroxy alprazolam (4-OHALP, pharmacologically less active) and ␣- V Ravindranath1,2 hydroxy alprazolam (␣-OHALP, pharmacologically more active). We exam- ined P450 mediated metabolism of alprazolam by rat and human brain 1Department of Neurochemistry, National microsomes and observed that the relative amount of ␣-OHALP formed in Institute of Mental Health & Neurosciences, brain was higher than liver. This biotransformation was mediated by a P450 Bangalore, India; 2National Brain Research Centre, ICGEB Campus, Aruna Asaf Ali Marg, isoform belonging to P4503A subfamily, which is constitutively expressed in New Delhi , India neuronal cells in rat and human brain. The formation of larger amounts of ␣-OHALP in neurons points to local modulation of pharmacological activity Correspondence: in brain, at the site of action of the anti-anxiety drug. Since hydroxy metab- V Ravindranath, National Brain Research olites of alprazolam are hydrophilic and not easily cleared through blood- Centre, ICGEB Campus, Aruna Asaf Ali ␣ Marg, New Delhi - 110 067, India CSF barrier, -OHALP would potentially have a longer half-life in brain. Tel: +91 124 630 8317 The Pharmacogenomics Journal (2002) 2, 243–258. -
Fact Sheet - Symptoms of Pancreatic Cancer
Fact Sheet - Symptoms of Pancreatic Cancer Diagnosis Pancreatic cancer is often difficult to diagnose, because the pancreas lies deep in the abdomen, behind the stomach, so tumors are not felt during a physical exam. Pancreatic cancer is often called the “silent” cancer because the tumor can grow for many years before it causes pressure, pain, or other signs of illness. When symptoms do appear, they can vary depending on the size of the tumor and where it is located on the pancreas. For these reasons, the symptoms of pancreatic cancer are seldom recognized until the cancer has progressed to an advanced stage and often spread to other areas of the body. General Symptoms Pain The first symptom of pancreatic cancer is often pain, because the tumors invade nerve clusters. Pain can be felt in the stomach area and/or in the back. The pain is generally worse after eating and when lying down, and is sometimes relieved by bending forward. Pain is more common in cancers of the body and tail of the pancreas. The abdomen may also be generally tender or painful if the liver, pancreas or gall bladder are inflamed or enlarged. It is important to keep in mind that there are many other causes of abdominal and back pain! Jaundice More than half of pancreatic cancer sufferers have jaundice, a yellowing of the skin and whites of the eyes. Jaundice is caused by a build-up bilirubin, a substance which is made in the liver and a component of bile. Bilirubin contains a lot of yellow pigment, and gives bile it’s color. -
Hepatitis B? HEPATITIS B Hepatitis B Is a Contagious Liver Disease That Results from Infection with the Hepatitis B Virus
What is Hepatitis B? HEPATITIS B Hepatitis B is a contagious liver disease that results from infection with the Hepatitis B virus. When first infected, a person can develop Are you at risk? an “acute” infection, which can range in severity from a very mild illness with few or no symptoms to a serious condition requiring hospitalization. Acute Hepatitis B refers to the first 6 months after someone is exposed to the Hepatitis B virus. Some people are able to fight the infection and clear the virus. For others, the infection remains and leads to a “chronic,” or lifelong, illness. Chronic Hepatitis B refers to the illness that occurs when the Hepatitis B virus remains in a person’s body. Over time, the infection can cause serious health problems. How is Hepatitis B spread? Hepatitis B is usually spread when blood, semen, or other body fluids from a person infected with the Hepatitis B virus enter the body of someone who is not infected. This can happen through having sex with an infected partner; sharing needles, syringes, or other injection drug equipment; or from direct contact with the blood or open sores of an infected person. Hepatitis B can also be passed from an infected mother to her baby at birth. Who should be tested for Hepatitis B? Approximately 1.2 million people in the United States and 350 million people worldwide have Hepatitis B. Testing for Hepatitis B is recommended for certain groups of people, including: Most are unaware of their infection. ■ People born in Asia, Africa, and other regions with moderate or high rates Is Hepatitis B common? of Hepatitis B (see map) Yes. -
Hepatitis A, B, and C: Learn the Differences
Hepatitis A, B, and C: Learn the Differences Hepatitis A Hepatitis B Hepatitis C caused by the hepatitis A virus (HAV) caused by the hepatitis B virus (HBV) caused by the hepatitis C virus (HCV) HAV is found in the feces (poop) of people with hepa- HBV is found in blood and certain body fluids. The virus is spread HCV is found in blood and certain body fluids. The titis A and is usually spread by close personal contact when blood or body fluid from an infected person enters the body virus is spread when blood or body fluid from an HCV- (including sex or living in the same household). It of a person who is not immune. HBV is spread through having infected person enters another person’s body. HCV can also be spread by eating food or drinking water unprotected sex with an infected person, sharing needles or is spread through sharing needles or “works” when contaminated with HAV. “works” when shooting drugs, exposure to needlesticks or sharps shooting drugs, through exposure to needlesticks on the job, or from an infected mother to her baby during birth. or sharps on the job, or sometimes from an infected How is it spread? Exposure to infected blood in ANY situation can be a risk for mother to her baby during birth. It is possible to trans- transmission. mit HCV during sex, but it is not common. • People who wish to be protected from HAV infection • All infants, children, and teens ages 0 through 18 years There is no vaccine to prevent HCV. -
Guidelines on the Management of Ascites in Cirrhosis
Downloaded from gut.bmjjournals.com on 25 September 2006 Guidelines on the management of ascites in cirrhosis K P Moore and G P Aithal Gut 2006;55;1-12 doi:10.1136/gut.2006.099580 Updated information and services can be found at: http://gut.bmjjournals.com/cgi/content/full/55/suppl_6/vi1 These include: References This article cites 148 articles, 21 of which can be accessed free at: http://gut.bmjjournals.com/cgi/content/full/55/suppl_6/vi1#BIBL Email alerting Receive free email alerts when new articles cite this article - sign up in the box at the service top right corner of the article Topic collections Articles on similar topics can be found in the following collections Liver, including hepatitis (945 articles) Notes To order reprints of this article go to: http://www.bmjjournals.com/cgi/reprintform To subscribe to Gut go to: http://www.bmjjournals.com/subscriptions/ Downloaded from gut.bmjjournals.com on 25 September 2006 vi1 GUIDELINES Guidelines on the management of ascites in cirrhosis K P Moore, G P Aithal ............................................................................................................................... Gut 2006;55(Suppl VI):vi1–vi12. doi: 10.1136/gut.2006.099580 1.0 INTRODUCTION N Grade 1 (mild). Ascites is only detectable by ultrasound examination. Ascites is a major complication of cirrhosis,1 occurring in 50% of patients over 10 years of N Grade 2 (moderate). Ascites causing moderate follow up.2 The development of ascites is an symmetrical distension of the abdomen. important landmark in the natural history of N Grade 3 (large). Ascites causing marked cirrhosis as it is associated with a 50% mortality abdominal distension. -
Procedure Coding in ICD-9-CM and ICD- 10-PCS
Procedure Coding in ICD-9-CM and ICD- 10-PCS ICD-9-CM Volume 3 Procedures are classified in volume 3 of ICD-9-CM, and this section includes both an Alphabetic Index and a Tabular List. This volume follows the same format, organization and conventions as the classification of diseases in volumes 1 and 2. ICD-10-PCS ICD-10-PCS will replace volume 3 of ICD-9-CM. Unlike ICD-10-CM for diagnoses, which is similar in structure and format as the ICD-9-CM volumes 1 and 2, ICD-10-PCS is a completely different system. ICD-10-PCS has a multiaxial seven-character alphanumeric code structure providing unique codes for procedures. The table below gives a brief side-by-side comparison of ICD-9-CM and ICD-10-PCS. ICD-9-CM Volume3 ICD-10-PCS Follows ICD structure (designed for diagnosis Designed and developed to meet healthcare coding) needs for a procedure code system Codes available as a fixed or finite set in list form Codes constructed from flexible code components (values) using tables Codes are numeric Codes are alphanumeric Codes are 3-4 digits long All codes are seven characters long ICD-9-CM and ICD-10-PCS are used to code only hospital inpatient procedures. Hospital outpatient departments, other ambulatory facilities, and physician practices are required to use CPT and HCPCS to report procedures. ICD-9-CM Conventions in Volume 3 Code Also In volume 3, the phrase “code also” is a reminder to code additional procedures only when they have actually been performed. -
Ultra-Sound Guided Liver Biopsy
Ultra-Sound Guided Liver Biopsy What is a liver biopsy? A liver biopsy is a procedure used for making the diagnosis of abnormal liver conditions. A small piece of liver tissue is removed using a special needle for examination under a microscope. The liver tissue allows the doctor to see if your liver is healthy or to better understand why you have liver damage or disease and how severe any damage is. The most common method of liver biopsy is percutaneously (“through the skin”). This procedure is often performed as an outpatient and does not routinely require hospital admission. A qualified gastroenterologist does the liver biopsy. This is a doctor who specializes in diseases of the digestive system and liver. Does the liver biopsy hurt? You may feel minor discomfort during the biopsy. Some people do have some discomfort at the site of the biopsy for the first 24 to 48 hours after the procedure but this is often relieved by simple painkillers such as Tylenol. Why do I need a liver biopsy? Your doctor will have discussed this with you or written to you about the need for a liver biopsy. If you have any questions, please ask. This test may be carried out for a number of reasons. Common indications include: Your symptoms, blood tests and scans (ultrasound, CT or MRI scans) suggest you have liver disease. However, sometimes it is not possible to tell what the cause is on the basis of these tests alone. There appears to be a lump in your liver which has been seen on previous scans and a sample of tissue is needed to identify what it is.